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Background: Medication safety in patients with chronic kidney disease (CKD) is a growing concern. This is
particularly relevant in older adults due to underlying CKD. Metformin use is contraindicated in patients with
abnormal kidney function; however, many patients are potentially prescribed metformin inappropriately. We
evaluated the prevalence of CKD among older adults prescribed metformin for type 2 diabetes mellitus using
available equations to estimate kidney function and examined demographic characteristics of patients who were
potentially inappropriately prescribed metformin.
Methods: We conducted a cross-sectional analysis of older adults aged ≥65 years prescribed metformin from
March 2008-March 2009 at an urban tertiary-care facility in Seattle, Washington, USA. CKD was defined using
National Kidney Foundation-Kidney Disease Outcomes Quality Initiative criteria. Creatinine clearance was calculated
using the Cockcroft-Gault equation; estimated glomerular filtration rate was calculated using the abbreviated
Modification of Diet in Renal Disease (MDRD) and CKD-Epidemiology (EPI) Collaboration equations. Regression analyses
were used to determine the associations between demographic characteristics and prevalent CKD.
Results: Among 356 subjects (median age 69 years, 52.5% female, 39.4% non-Hispanic black), prevalence of stage 3 or
greater CKD calculated by any of the equations was 31.4%. The Cockcroft-Gault equation identified more subjects as
having CKD (23.7%) than the abbreviated MDRD (21.1%) or CKD-EPI (21.7%) equations (P < 0.001). Older age (OR = 1.13,
95% CI 1.08-1.19) and female sex (OR = 2.51, 95% CI 1.44-4.38) were associated with increased odds of potentially
inappropriate metformin prescription due to CKD; non-Hispanic black race was associated with decreased odds of
potentially inappropriate metformin prescription due to CKD (OR = 0.41, 95% CI 0.23-0.71).
Conclusions: CKD is common in older adults prescribed metformin for type 2 diabetes, raising concern for
potentially inappropriate medication use. No single equation to estimate kidney function may accurately identify
CKD in this population. Medication safety deserves greater consideration among elderly patients due to the
widespread prevalence of CKD.
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Medication safety in older adults is a growing concern,
particularly in those with chronic kidney disease (CKD).
Although new CKD estimating equations such as the ab-
breviated Modification of Diet in Renal Disease (MDRD)
Study equation [1] and Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) formula [2] are
available, pharmacists tasked with the delivery of medi-
cations tend to use the older Cockcroft-Gault formula
[3] to estimate CKD according to pharmaceutical manu-
facturer recommendations [4]. Metformin is an effective
medication commonly prescribed to treat type 2 diabetes
mellitus, but its use is potentially limited in adults ≥65 years
of age due to increased prevalence of CKD [5,6]. The
American Geriatrics Society recently recommended using
estimated glomerular filtration rate (eGFR) to guide met-
formin use in older adults with diabetes: metformin
should not be used when eGFR < 30 mL/min/1.73 m2,
and lower dosages are recommended for eGFR 30–
60 mL/min/1.73 m2, with more frequent kidney function
monitoring [7]. Current U.S. drug labeling includes “renal
impairment” (defined as “serum creatinine greater than
or equal to 1.5 mg/dL [133 μmol/L] [males] or 1.4 mg/dL
[124 μmol/L] [females] or an abnormal creatinine
clearance”) as a contraindication to using metformin
[8]. Additional precautions for older adults recommend
“conservative” dosing, and to only start metformin in
adults ≥80 years of age if creatinine clearance is normal
[8,9]. A black box warning was issued by the U.S. Food
and Drug Administration regarding the increased risk
of metformin-associated lactic acidosis with older age as
well as impaired kidney function [8], though metformin-
associated lactic acidosis is a rare complication [10]. Thus,
older adults are at higher risk of developing adverse events
when using metformin due to underlying impaired kidney
function.
The National Kidney Foundation (NKF) defines CKD
as “either kidney damage [defined as pathologic abnor-
malities or markers of damage including abnormal
blood, urine or imaging tests] or GFR [glomerular filtra-
tion rate] <60 mL/min/1.73 m2 for ≥3 months” [11].
Current available methods used in clinical practice to es-
timate GFR include: 1) calculating creatinine clearance
using the Cockcroft-Gault equation; 2) calculating eGFR
using the abbreviated MDRD equation; or 3) the CKD-
EPI formula. These equations may not accurately esti-
mate kidney function for older adults [12,13] and are
reported to give discordant results among older adults
with an eGFR ≥60 mL/min/1.73 m2 [13-17]. Prescribing
clinicians and clinical pharmacists may use different
equations to estimate kidney function [4], which may
lead to conflicting opinions regarding appropriate use
of metformin due to disparities in estimated kidney
function. Additionally, there are no uniform U.S. clinicalpractice guidelines for metformin use in kidney impair-
ment and considerable variation in recommendations
worldwide [18].
Few studies describe the prevalence of CKD in older
adults (≥65 years of age) with diabetes mellitus, particu-
larly among those taking metformin. Reported prevalence
of CKD among U.S. older adults ranges from 25.9-44%
[5,6,19]. A UK study reported 49% of adults ≥70 years old
with diabetes mellitus had CKD stage 3 or higher [20].
Improved recognition of CKD in older adults with dia-
betes mellitus is needed to identify patients at increased
risk of serious adverse events and to determine appropri-
ate treatment plans. We hypothesized that older adults
with CKD were at risk for potentially inappropriate treat-
ment with metformin. The current study reports the
prevalence of CKD among older adults with type 2 dia-
betes mellitus prescribed metformin at an urban tertiary-
care facility and compares the prevalence of CKD using
the Cockcroft-Gault, abbreviated MDRD and CKD-EPI
equations to estimate kidney function.
Methods
Study subjects
Outpatient pharmacy records were reviewed to identify
subjects meeting study inclusion criteria: aged ≥65 years
who filled a prescription for metformin at any of the
Harborview Medical Center (Seattle, Washington) out-
patient pharmacies from March 1, 2008 to March 1,
2009. The diagnosis of type 2 diabetes mellitus was as-
sumed for older adults prescribed metformin; older
adults are unlikely to be taking metformin for off-label
conditions. Three hundred fifty-six subjects were identi-
fied who met study inclusion criteria. The Harborview
Medical Center outpatient pharmacy fills approximately
80% of prescriptions ordered at the facility for both out-
patients and inpatients upon hospital discharge; the re-
mainder of prescriptions are filled at outside pharmacies.
The initial metformin prescription filled was used for
subjects who obtained multiple metformin prescriptions
during the study period. This study was approved by
the IRB at the University of Washington (University of
Washington Human Subjects Divison).
Data collection
Age, sex, race/ethnicity, weight, serum creatinine, reported
eGFR, prescribing provider and primary care provider were
abstracted from the electronic medical record. Access to
the electronic medical records used for this study is not
freely available; permission to access these records was
granted by Harborview Medical Center after study ap-
proval by the University of Washington Human Subjects
Division. The most recent reported values for weight,
serum creatinine and eGFR prior to the earliest metformin
prescription were used to estimate kidney function. Serum
Table 1 Characteristics of subjects prescribed metformin
Characteristic Result
N = 356








Serum creatinine, μmol/L, median (IQR)a 80 (70, 97)
Creatinine clearance (Cockcroft-Gault), mL/min,
median (IQR)b
76 (60, 94)
Estimated glomerular filtration rate, mL/min/1.73 m2a
Abbreviated MDRD Study equation, median (IQR) 74 (61, 87)
CKD-EPI equation, mean ± SD (range) 76 ± 19 (21–118)
Prevalence of chronic kidney disease stage 3 or
higher by any measure, N (%)
110 (31.4%)
IQR interquartile range (25th, 75th percentile).
SD standard deviation.
aN = 350, serum creatinine values not reported for 6 subjects.
bN = 337, serum creatinine, race or weight not reported for 26 subjects.
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prior to the earliest metformin prescription fill date.
Estimates of kidney function: outcome of interest
Three methods were used to calculate estimated kidney
function: the Cockcroft-Gault equation [3], abbreviated
MDRD Study equation [1] and CKD-EPI formula [2] as
outlined below.
Cockcroft‐Gault creatinine clearance mL=minð Þ
¼ 140−ageð Þ  lean body weight kgð Þ½   C
serum creatinine μmol=Lð Þ½ 
(C = 1.23 for males, 1.04 for females)
Abbreviated MDRD eGFR mL=min=1:73m2ð Þ
¼ 175  serum creatinine μmol=Lð Þ=88:4½ ‐1:154
 ageð Þ‐0:203  0:742 if femaleð Þ
 1:212 if African‐Americanð Þ
CKD−EPI eGFR mL=min=1:73 m2ð Þ ¼ 141
min SCr μmol=Lð Þ=88:4ð Þ=κ; 1½ α
max SCr μmol=Lð Þ=88:4ð Þ=κ; 1½ −1:209
0:993age  1:018 if femaleð Þ
 1:159 if African−Americanð Þ
κ = 0.7 if female, 0.9 if male
α = −0.329 if female, −0.411 if male
min = the minimum of SCr/κ or 1
max = the maximum of SCr/κ or 1
CKD stage was identified from the calculated eGFR as
defined by NKF Kidney Disease Outcome Quality Initiative
(KDOQI) Clinical Practices for CKD [11]. Subjects were
categorized as follows: stage 1–2 = eGFR ≥60 mL/min/
1.73 m2, stage 3 = eGFR 30–59 mL/min/1.73 m2, stage
4 = eGFR 15–29 mL/min/1.73 m2, stage 5 = eGFR <15 mL/
min/1.73 m2.
Statistical analysis
Continuous variables were examined for normal distri-
bution. Descriptive analyses of the above variables were
performed and stratified by sex and race using non-
parametric equality-of-medians tests (continuous variables)
and Chi-square tests (categorical variables). Frequency of
CKD (defined as CKD stage 3 or higher estimated by any of
the equations for this study) was determined for the entire
study population and separately for CKD calculated by each
estimated kidney function equation. Logistic regression ana-
lyses were performed to determine the association between
CKD (outcome of interest) and age, sex, weight and race
(predictors of interest), and for those with CKD estimated
by each equation. Statistical analysis was performed using
STATA/IC 11.2 (StataCorp LP, College Station, TX).Results
Characteristics of the 356 eligible subjects identified
from pharmacy records are shown in Table 1. Estimated
creatinine clearance could not be calculated for 19 sub-
jects due to missing serum creatinine or weight mea-
surements, and eGFR could not be calculated for 6
subjects due to missing serum creatinine values or race/
ethnicity. The study population had a median age of
69 years (interquartile range 66, 74 with range 65–89
years) and 39.4% were non-Hispanic black. The overall
prevalence of CKD (defined as stage 3 or higher calcu-
lated by any of the equations) was 31.4%.
Comparison of the estimated kidney function mea-
surements for subjects identified as having CKD is
shown in Table 2. Each equation identified more sub-
jects as having CKD than abnormal serum creatinine
alone as defined by the drug label (N = 14, 3.9%) [8,9].
The Cockcroft-Gault equation identified more subjects
as having CKD (N = 80, 23.7%) compared to the abbrevi-
ated MDRD (N = 74, 21.1%) and CKD-EPI equations
(N = 76, 21.7%) (P <0.001). The proportion of subjects cat-
egorized with CKD stages 3 and 4 were not significantly
different between equations (Table 2). A small number of
subjects received prescriptions for metformin despite a
calculated creatinine clearance or eGFR <30 mL/min/
1.73 m2. Median serum creatinine and eGFR were sig-
nificantly lower in subjects with CKD identified by the
Cockcroft-Gault equation. Subjects with CKD identified
Table 2 Comparison of subjects with chronic kidney disease (CKD) estimated by the Cockcroft-Gault, abbreviated
MDRD and CKD-EPI equations
Cockcroft-Gault Abbreviated MDRD CKD-EPI P-value
Frequency CKD stage 3 or higher, N (%) 80 (23.7%) 74 (21.1%) 76 (21.7%) <0.001
Stage 3 (30–59 mL/min/1.73 m2) 78 (97.5%) 73 (98.7%) 75 (98.7%) 0.9
Stage 4 (15–29 mL/min/1.73 m2) 2 (2.5%) 1 (1.4%) 1 (1.3%) 0.8
Stage 5 (<15 mL/min/1.73 m2) 0 0 0 0.9
Serum creatinine, μmol/L, median (IQR) 97 (80, 115) 106 (88, 124) 106 (88, 124) <0.001c
Estimated glomerular filtration rate, median (IQR) 47.5 (41, 55) 53 (45, 55) 52 (47, 57) <0.001c
IQR interquartile range (25th, 75th percentile).
cQuantile regression to compare medians.
MDRD Modification of Diet in Renal Disease Study.
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration.
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compared to those identified by the abbreviated MDRD
and CKD-EPI equations. Figure 1 demonstrates both
concordance and discordance between creatinine clearance
and eGFR values in the study population. Discordance be-
tween calculated creatinine clearance and eGFR calculated
by either the abbreviated MDRD or CKD-EPI equations
was 18.9%.
Table 3 shows results of the multivariable logistic
regression models. Older subjects had 13% greater likeli-
hood of potentially inappropriate metformin prescription
due to CKD defined by any equation (OR = 1.13, 95% CI
1.08-1.19, P < 0.001) and female subjects had 2.51-fold
greater likelihood of potentially inappropriate metformin
prescription due to CKD (OR = 2.51, 95% CI 1.44-4.38,
P = 0.001). Non-Hispanic black subjects had 59% decreased
odds of potentially inappropriate metformin prescription
due to CKD (OR = 0.41, 95% CI 0.23-0.71, P = 0.001).
Comparison of CKD as calculated by each equation
showed that older age was consistently associated with
increased odds of potentially inappropriate metformin
prescription due to CKD (Table 3). Female subjects
had 3.22-fold greater likelihood of potentially inappro-
priate metformin prescription due to CKD calculated
by the abbreviated MDRD equation (OR = 3.22, 95% CIFigure 1 Comparison of creatinine clearance with GFR estimated by a1.70-6.12, P < 0.001) and 2.44-fold greater likelihood of
CKD calculated by the CKD-EPI equation (OR = 3.44,
95% CI 1.81-6.53, P < 0.001). Female subjects did not
have significantly increased odds of potentially inappro-
priate metformin prescription due to CKD calculated
by the Cockcroft-Gault equation (OR = 1.03, 95% CI
0.52-2.04, P = 0.94). Regression analyses showed signifi-
cantly decreased odds of potentially inappropriate met-
formin prescription due to CKD for non-Hispanic blacks
when the abbreviated MDRD and CKD-EPI equations
were used, but not with the Cockcroft-Gault equation
(Table 3).
Discussion
CKD stage 3 or higher was common in this study popu-
lation, affecting 31.4% of older adults with type 2 dia-
betes mellitus prescribed metformin at an urban tertiary
care setting. This can neither be directly compared to
previously reported estimates of CKD among all adults
with diabetes mellitus, which range from 15.1% in the
U.S. [21], 27.5-31% in the UK [20,22] and 38% in urban
Japanese adults [23]; nor can this result be directly com-
pared to a previous UK study which reported that 49% of
adults ≥70 years old with diabetes had CKD stage 3 or
higher [20], or a recent Canadian study that showedbbreviated MDRD and CKD-EPI equations.
Table 3 Logistic regression models for metformin use and association with chronic kidney disease (CKD) and
demographic characteristics
Age Female Weight Non-Hispanic black
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Any CKDd 1.13 (1.08-1.19) <0.001 2.51 (1.44-4.38) 0.001 0.99 (0.98-1.01) 0.32 0.41 (0.23-0.71) 0.001
CKD calculated by Cockcroft-Gaultd 1.16 (1.10-1.23) <0.001 1.03 (0.52-2.04) 0.94 0.92 (0.90-0.95) <0.001 0.76 (0.39-1.50) 0.43
CKD calculated by MDRDd 1.09 (1.04-1.14) 0.001 3.22 (1.70-6.12) <0.001 1.02 (1.00-1.03) 0.01 0.33 (0.17-0.62) 0.001
CKD calculated by CKD-EPId 1.11 (1.05-1.16) <0.001 3.44 (1.81-6.53) <0.001 1.02 (1.01-1.03) 0.005 0.38 (0.20-0.71) 0.002
MDRD Modification of Diet in Renal Disease Study.
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration.
CKD defined as stage 3 or higher (<60 mL/min/1.73 m2) by either the Cockcroft-Gault, abbreviated MDRD or CKD-EPI equations.
dMultivariable logistic regression model P < 0.001.
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prescription for diabetes had CKD stage 3 or higher [24].
However, this study result may reflect kidney function of
older adults with type 2 diabetes.
The Cockcroft-Gault, abbreviated MDRD and CKD-EPI
equations were comparable in estimating CKD prevalence
in the study population, though the Cockcroft-Gault equa-
tion identified more subjects as having CKD. Median
serum creatinine was in the normal range and median
eGFR was lower among subjects with CKD identified by
the Cockcroft-Gault equation compared to those with
CKD identified by the other equations. This demonstrates
some discrepancy between estimated kidney function re-
sults using the Cockcroft-Gault equation and either the
abbreviated MDRD Study equation or the CKD-EPI for-
mula (Figure 1). This may be due to our study population
consisting of older adults and racial/ethnic minorities,
which were not well represented in the original popula-
tions used to derive these equations [1-3]. Additionally,
some discrepancy may be due to the fact that the CKD-
EPI equation is reported to be more accurate for estimat-
ing GFR >60 mL/min/1.73 m2 [25].
The multivariable logistic regression models showed
differences in the association between CKD, sex and
race/ethnicity, particularly in the comparison of CKD es-
timated by each equation. All three equations showed
that increased age was consistently associated with po-
tentially inappropriate metformin prescription due to
CKD as expected. However, the Cockcroft-Gault equa-
tion did not demonstrate statistically significant in-
creased odds of potentially inappropriate metformin
prescription due to CKD for female sex compared to
the abbreviated MDRD and CKD-EPI equations. It also
did not show statistically significant decreased odds of
potentially inappropriate metformin prescription due to
CKD for non-Hispanic blacks compared to the other
equations. This is likely due to the sex and racial/ethnic
differences in our study population, as the Cockcroft-
Gault equation was derived mostly from Caucasian males
[3]. In contrast, the abbreviated MDRD and CKD-EPIequations both showed significant associations between
CKD, female sex and non-Hispanic black race.
It is worth noting that the Cockcroft-Gault equa-
tion is generally used to adjust medication doses for
impaired kidney function and creatinine clearance is
used in drug labeling. Clinical pharmacists primarily
use the Cockcroft-Gault equation rather than the MDRD
or CKD-EPI equations to estimate kidney function ac-
cording to pharmaceutical manufacturer recommenda-
tions; a small survey of U.S. clinical pharmacists showed
that nearly all used the Cockcroft-Gault equation to ad-
just dosing in kidney impairment and use of the abbrevi-
ated MDRD equation varied [4]. However, prescribing
clinicians may be more likely to use eGFR (calculated
from either the abbreviated MDRD equation or CKD-EPI
formula) automatically reported by laboratories to evalu-
ate kidney function, because creatinine clearance must be
calculated.
It is questionable whether these eGFR discrepancies
would significantly impact clinical practice in prescribing
metformin. Changes in kidney function would affect a
prescribing clinician’s decision to use metformin, or pos-
sibly decreasing the metformin dose due to decreasing
kidney function. However, these results may indicate
that using eGFR calculated from the Cockcroft-Gault
equation may lead clinicians to discontinue metformin
earlier than using eGFR calculated from either the ab-
breviated MDRD or CKD-EPI equations. It may be
worthwhile to consider whether larger studies would
help determine if a different CKD threshold could be
used to safely prescribe metformin to older adults given
the rarity of serious adverse events. Metformin-associated
lactic acidosis is infrequently reported: a 2010 Cochrane re-
view did not identify any cases of lactic acidosis from
pooled data including 70,490 patient-years of metformin
use, and estimated the incidence of lactic acidosis as 4.3
cases per 100,000 patient-years [10]. A recent observational
study reported no increased risk of metformin-associated
lactic acidosis among 51,675 Swedish adults with type 2
diabetes and kidney dysfunction [26]. Bodmer et al.
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control analysis of UK subjects with type 2 diabetes
taking oral medications; the estimated crude incidence
rate was 3.3 cases per 100,000 patient-years [27]. Kamber
et al. reported 5 cases of lactic acidosis in the Fremantle
Diabetes Study group with an estimated incidence of 57/
100,000 patient-years [28]. A study of U.S. adults with
type 2 diabetes and CKD stage 3 nephropathy (N = 237)
did not report any cases of lactic acidosis [29]. Thus, it
may be inferred that the majority of older adults with
diabetes and kidney impairment continue to use metfor-
min safely.
Potential advantages for using metformin in older
adults include that it is usually well-tolerated; GI adverse
effects are typically dose-related and may be reduced
with concurrent food intake. Metformin has a low likeli-
hood of causing hypoglycemia as a single-drug treatment
and causes less weight gain, both of which may be ad-
vantages for use in older adults. Its use may potentially
delay the need for insulin, which may be difficult for
older adults to administer and impact ability to live in-
dependently. Risk of metformin-associated lactic acidosis
in this population may be reduced by routinely discon-
tinuing it for anticipated changes in kidney function dur-
ing acute illness and surgical procedures. Additional
larger studies would be helpful to assess the benefits and
risks of using metformin in older adults with type 2
diabetes.
This study has several potential limitations of note. A
single serum creatinine value was used to calculate cre-
atinine clearance and eGFR, as some subjects only had
one serum creatinine value during the study period; 6
subjects had no recorded serum creatinine during the
study period. This may have led to over-estimation of
CKD, as we were unable to determine whether serum
creatinine values were stable for ≥3 months. However,
prescribing clinicians and pharmacists are more likely to
use the most current serum creatinine value to guide
clinical decision-making. Another limitation is that the
study sample may not be representative of the general
population in the United States with a greater number
of Asian and Pacific Islanders who live in the Seattle
area. This may under-estimate the prevalence of CKD as
calculated by the MDRD and CKD-EPI equations. Lactic
acidosis was not evaluated as an outcome due to diffi-
culty identifying true metformin-associated lactic acid-
osis in a retrospective electronic medical record review
as well as the rare frequency of metformin-associated
lactic acidosis.
Despite the study’s limitations, we found a high CKD
prevalence in older adults aged ≥65 years who were
prescribed metformin for type 2 diabetes. CKD preva-
lence differed by the estimating equation used, but met-
formin was potentially inappropriately prescribed in alarge proportion of this study population. The discrep-
ancy between estimated kidney function calculated by
the Cockcroft-Gault equation, the abbreviated MDRD
Study equation and the CKD-EPI equation highlights the
need for better methods to easily and accurately evaluate
kidney function in the clinical practice setting with re-
sults readily available to all providers, including pharma-
cists. Prescribing clinicians and pharmacists may use
different equations to estimate kidney function, which af-
fects prescribing practices and evaluation of medication
safety. Systems changes may also be useful to help clini-
cians and pharmacists determine when it is appropriate
to prescribe metformin for those with CKD, especially in
older adults. Possible future studies would include a lon-
gitudinal assessment of this population’s kidney function
and lactic acidosis events, as well as comparing kidney
function measurements with older adults taking other
diabetes medications.
Conclusions
The estimated prevalence of CKD was 31.4% in this
study population of older adults prescribed metformin
for type 2 diabetes mellitus, which raises the possibility
of potentially inappropriate metformin use. The Cockcroft-
Gault equation identified more subjects as having CKD
than the abbreviated MDRD or CKD-EPI equations. This
discrepancy emphasizes the need for an accurate and read-
ily available method to easily determine kidney function of
older adults in clinical practice settings. These differences
in estimated kidney function may lead to disagreements
between prescribing clinicians and clinical pharmacists in
determining safety of metformin use.
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